Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Interleukin-6 (IL-6) is crucial in pancreatic ductal adenocarcinoma (PDAC) progression and survival.
• Targeting the IL-6/glycoprotein-130 (gp130) pathway is a potential therapeutic strategy for PDAC.

Purpose of the Study:

• To evaluate if SC144 (gp130 inhibitor) or raloxifene enhances paclitaxel efficacy in PDAC.
• To investigate the combined effects on cell viability, proliferation, and apoptosis in vitro and in vivo.

Main Methods:

• In vitro studies used MTT/BrdU assays and TUNEL staining in human PDAC cell lines.
• In vivo studies utilized an orthotopic PDAC mouse model with tumor analysis via qPCR, IHC, and ELISA.
• Synergy scores were calculated to assess drug interactions.

Main Results:

• Paclitaxel combined with raloxifene, but not SC144, showed enhanced anti-proliferative and pro-apoptotic effects in vitro.
• Both raloxifene/paclitaxel and SC144/paclitaxel combinations significantly reduced tumor weight and volume in vivo.
• Raloxifene/paclitaxel decreased survivin and increased cleaved caspase-3, while SC144/paclitaxel reduced IL-6 levels.

Conclusions:

• Raloxifene and SC144 can potentiate paclitaxel's anti-tumorigenic effects in PDAC.
• Combined therapy may allow for reduced paclitaxel dosage, potentially mitigating side effects.
• Targeting IL-6 signaling offers a promising approach for enhancing chemotherapy in pancreatic cancer.